Action to Control Cardiovascular Risk in Diabetes (ACCORD)

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
• Collaborators: Centers for Disease Control and Prevention; National Eye Institute (NEI); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute on Aging (NIA)
• Treatments: Acarbose; Amlodipine; Antihypertensive Agents; Benazepril; Candesartan; Candesartan cilexetil; Carvedilol; Chlorthalidone; Diltiazem; Felodipine; Fenofibrate; Furosemide; Glimepiride; Hydralazine; Hydrochlorothiazide; Hydrochlorothiazide-triamterene; Hydrochlorothiazide, lisinopril drug combination; Hypoglycemic Agents; Insulin; Insulin Aspart; Insulin Detemir; Insulin Glargine; Insulin, Globin Zinc; Lisinopril; Metformin; Metoprolol; Pioglitazone; Repaglinide; Reserpine; Rosiglitazone; Simvastatin; Terazosin; Triamterene; Valsartan

Criteria

Inclusion Criteria:

• Diagnosed with type 2 diabetes mellitus, as determined by the new American Diabetes Association guidelines, which include a fasting plasma glucose level greater than 126 mg/dl (7.0 mmol/l), or a 2-hour postload value in the oral glucose tolerance test of greater than 200 mg/dl, with confirmation by a retest

• For participants aged 40 years or older, history of CVD (heart attack, stroke, history of coronary revascularization, history of peripheral or carotid revascularization, or demonstrated angina)

• For participants aged 55 years or older, a history of CVD is not required, but participant must be considered to be at high risk for experiencing a CVD event due to existing CVD, subclinical disease, or 2+ CVD risk factors

• HbA1c 7.5%-9% (if on more drugs) or 7.5%-11% (if on fewer drugs)